Key Performance
More- Earnings Score: N/A
- Momentum Score: 92
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. (Nasdaq: BDSX) announced that its leadership team will participate in three upcoming investor conferences in May and June 2026, including Craig-Hallum, William Blair Growth Stock Conference, and TD Cowen Annual Tools/Dx Revolution. The company will hold 1x1 meetings and present at select events, with presentations available for webcast replay.
05/21/2026, 6:00 AM • GlobeNewswire
Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026
Biodesix, Inc. (Nasdaq: BDSX) announced it will release first quarter 2026 financial results on May 4, 2026, after market close, followed by a management conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update.
04/20/2026, 6:00 AM • GlobeNewswire
Biodesix to Participate in Upcoming Investor Conferences
Biodesix, Inc. announced preliminary Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 2025. Management will participate in investor conferences in March 2026.
02/24/2026, 6:00 AM • GlobeNewswire
Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Biodesix reported estimated Q4 2025 revenue of $28.8 million (41% increase) and full-year 2025 revenue of $88.5 million (24% increase). The company affirmed guidance for Adjusted EBITDA positivity in Q4 and plans to present clinical utility data for its Nodify Lung tests at upcoming scientific meetings.
02/12/2026, 6:00 AM • GlobeNewswire
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)
Biodesix reported Q4 2025 revenue of $28.8 million (41% increase) and full-year revenue of $88.5 million (24% increase), exceeding guidance. Lung Diagnostics revenue grew 47% in Q4 driven by increased test volumes and reimbursement expansion. The company affirmed expectations for positive Adjusted EBITDA in Q4 2025.
01/12/2026, 6:00 AM • GlobeNewswire
Biodesix's CFO Robin Cowie will host investor meetings at the Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference in New York on September 11, 2025.
09/05/2025, 6:00 AM • GlobeNewswire
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference
Biodesix will present at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025, with CEO Scott Hutton and CFO Robin Cowie hosting a fireside chat and investor meetings in Boston, MA.
08/05/2025, 6:00 AM • GlobeNewswire
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025
Biodesix will release its second quarter 2025 financial results on August 7, hosting a conference call and webcast to discuss financial performance and provide a business update.
07/24/2025, 6:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.